Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of JNJ-55375515 in Healthy Subjects
NCT02623491Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-55375515 in cognitive disorder (CD) and psychosis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Time to Reach Maximum Observed Plasma Concentration and 3 more. Started Nov 2015; status: completed.
02
Drugs
JNJ-55375515
03
Conditions
cognitive disorder (CD)psychosis
Beyond the preview
Go deeper on NCT02623491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623491.